drugset / Trial / NCT00110721

GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

NCT00110721

Phase 2 Terminated 20 enrolled Galectin Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II, multi-center study of GM-CT-01 which has been shown to increase the anti-tumor activity of 5-fluorouracil (5-FU) in mice. 5-FU is a chemotherapy drug commonly used in cancer patients. In this Phase II study, patients with colon cancer which has spread, despite treatment with approved therapies, will receive GM-CT-01 plus 5-FU in monthly cycles for at least 2 cycles or until their disease progresses.

Timeline

Start
2005-05
Primary completion
2007-06
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject DAVANAT Other / unclassified 280 mg/m2 Intravenous
Subject fluorouracil Small molecule 500 mg/m2

Indications